Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 3
1975 4
1976 4
1977 2
1978 1
1979 5
1980 4
1981 7
1982 2
1983 8
1984 3
1986 4
1987 5
1988 4
1989 3
1990 1
1991 5
1992 10
1993 12
1994 5
1995 6
1996 8
1997 11
1998 16
1999 17
2000 16
2001 21
2002 20
2003 18
2004 23
2005 26
2006 23
2007 23
2008 26
2009 29
2010 23
2011 32
2012 25
2013 32
2014 39
2015 33
2016 37
2017 34
2018 33
2019 37
2020 39
2021 54
2022 60
2023 56
2024 24

Text availability

Article attribute

Article type

Publication date

Search Results

857 results

Results by year

Filters applied: . Clear all
Page 1
Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial.
Santer P, Anstey MH, Patrocínio MD, Wibrow B, Teja B, Shay D, Shaefi S, Parsons CS, Houle TT, Eikermann M; MIDAS Study Group. Santer P, et al. Intensive Care Med. 2020 Oct;46(10):1884-1893. doi: 10.1007/s00134-020-06216-x. Epub 2020 Sep 3. Intensive Care Med. 2020. PMID: 32885276 Free PMC article. Clinical Trial.
Time to vasopressor discontinuation was not different between midodrine and placebo groups (median [IQR], 23.5 [10-54] vs 22.5 [10.4-40] h; difference, 1 h; 95% CI - 10.4 to 12.3 h; p = 0.62). No differences in secondary endpoints were observed. Bradycardia occurred more o …
Time to vasopressor discontinuation was not different between midodrine and placebo groups (median [IQR], 23.5 [10-54] vs 22.5 [10.4- …
Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial.
Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, Bernardi M, Romanelli RG, Colletta C, Salinas F, Di Giacomo A, Ridola L, Fornasiere E, Caraceni P, Morando F, Piano S, Gatta A, Angeli P; Italian Association for the Study of the Liver Study Group on Hepatorenal Syndrome. Cavallin M, et al. Hepatology. 2015 Aug;62(2):567-74. doi: 10.1002/hep.27709. Epub 2015 Feb 13. Hepatology. 2015. PMID: 25644760 Free article. Clinical Trial.
Where terlipressin is not available, as in the United States, midodrine and octreotide with albumin are used as an alternative treatment of HRS. ...CONCLUSION: Terlipressin plus albumin is significantly more effective than midodrine and octreotide plus albumin in im …
Where terlipressin is not available, as in the United States, midodrine and octreotide with albumin are used as an alternative treatm …
Putting midodrine on the MAP: An approach to liberation from intravenous vasopressors in vasodilatory shock.
Smith SE, Peters NA, Floris LM, Patterson JM, Hawkins WA. Smith SE, et al. Am J Health Syst Pharm. 2022 Jun 23;79(13):1047-1055. doi: 10.1093/ajhp/zxac069. Am J Health Syst Pharm. 2022. PMID: 35235946 Review.
Acceleration of vasopressor liberation can aid in reducing these risks. Midodrine is an oral alpha 1-adrenergic receptor agonist that offers a potential means of liberating patients from IV vasopressor therapy. ...In observational studies, midodrine administration w …
Acceleration of vasopressor liberation can aid in reducing these risks. Midodrine is an oral alpha 1-adrenergic receptor agonist that …
Midodrine for severe orthostatic hypotension.
[No authors listed] [No authors listed] Drug Ther Bull. 2016 May;54(5):54-6. doi: 10.1136/dtb.2016.5.0399. Drug Ther Bull. 2016. PMID: 27173783 Review.
Midodrine (Bramox-Brancaster Pharma Limited) was authorised in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA) in March 2015 for "the treatment of severe orthostatic hypotension due to autonomic dysfunction in adults when corrective factors have be …
Midodrine (Bramox-Brancaster Pharma Limited) was authorised in the UK by the Medicines and Healthcare products Regulatory Agency (MHR …
Midodrine: Associated Bradycardia.
Cordeiro N, Gupta SS, Lindsay D, Seneviratne C, Kulbak G, Kupfer Y. Cordeiro N, et al. Am J Ther. 2019 Sep/Oct;26(5):e655-e656. doi: 10.1097/MJT.0000000000000856. Am J Ther. 2019. PMID: 31498780 No abstract available.
Exploring the Efficacy of Midodrine for Tapering Off Vasopressors.
Athar ZM, Arshad M, Shrivastava S. Athar ZM, et al. Cureus. 2024 Feb 28;16(2):e55192. doi: 10.7759/cureus.55192. eCollection 2024 Feb. Cureus. 2024. PMID: 38558716 Free PMC article. Review.
However, the efficacy of midodrine remains questionable, with conflicting evidence from clinical trials and meta-analyses. ...Ongoing efforts aim to address knowledge gaps surrounding midodrine's efficacy and safety....
However, the efficacy of midodrine remains questionable, with conflicting evidence from clinical trials and meta-analyses. ...Ongoing …
Midodrine in end-stage heart failure.
Gonzalez-Cordero A, Ortiz-Troche S, Nieves-Rivera J, Mesa-Pabón M, Franqui-Rivera H. Gonzalez-Cordero A, et al. BMJ Support Palliat Care. 2023 Oct;13(e1):e86-e87. doi: 10.1136/bmjspcare-2020-002369. Epub 2020 Jun 24. BMJ Support Palliat Care. 2023. PMID: 32581003
He did not qualify for heart transplantation or left ventricular-assist device strategies. Midodrine was started as a last resort attempt to wean off vasopressors. ...By the time of discharge, he was tolerating low-dose carvedilol along with midodrine. We propose …
He did not qualify for heart transplantation or left ventricular-assist device strategies. Midodrine was started as a last resort att …
Midodrine for orthostatic hypotension and recurrent reflex syncope: A systematic review.
Izcovich A, González Malla C, Manzotti M, Catalano HN, Guyatt G. Izcovich A, et al. Neurology. 2014 Sep 23;83(13):1170-7. doi: 10.1212/WNL.0000000000000815. Epub 2014 Aug 22. Neurology. 2014. PMID: 25150287 Review.
The most frequent side effects in the midodrine arm were pilomotor reactions (33.6%, risk ratio 4.58 [95% CI 2.03-10.37]). CONCLUSIONS: Evidence warranting low/moderate confidence suggests that midodrine improves clinical important outcomes in patients with SOH and …
The most frequent side effects in the midodrine arm were pilomotor reactions (33.6%, risk ratio 4.58 [95% CI 2.03-10.37]). CONCLUSION …
Midodrine and octreotide in treatment of cirrhosis-related hemodynamic complications.
Karwa R, Woodis CB. Karwa R, et al. Ann Pharmacother. 2009 Apr;43(4):692-9. doi: 10.1345/aph.1L373. Epub 2009 Mar 18. Ann Pharmacother. 2009. PMID: 19299324 Review.
OBJECTIVE: To review studies evaluating the use of midodrine and octreotide in hemodynamic complications of cirrhosis, including ascites and hepatorenal syndrome. ...In hepatorenal syndrome, patients using midodrine with octreotide showed significant changes in syst …
OBJECTIVE: To review studies evaluating the use of midodrine and octreotide in hemodynamic complications of cirrhosis, including asci …
Midodrine. A review of its therapeutic use in the management of orthostatic hypotension.
McClellan KJ, Wiseman LR, Wilde MI. McClellan KJ, et al. Drugs Aging. 1998 Jan;12(1):76-86. doi: 10.2165/00002512-199812010-00007. Drugs Aging. 1998. PMID: 9467688 Review.
Oral midodrine significantly increases 1-minute standing systolic blood pressure compared with placebo. ...Thus, oral midodrine is an effective therapeutic option for the management of various forms of orthostatic hypotension. ...
Oral midodrine significantly increases 1-minute standing systolic blood pressure compared with placebo. ...Thus, oral midodrine …
857 results